PMH40 - COST-MINIMISATION ANALYSIS OF SECOND GENERATION LONG ACTING INJECTABLES (RISPERIDONE , PALIPERIDONE, AND ARIPIPRAZOLE) FOR SCHIZOPHRENIA IN SPANISH MEDIUM-LONG TERM CARE PSYCHIATRIC UNITS
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.1675
https://www.valueinhealthjournal.com/article/S1098-3015(18)34977-5/fulltext
Title :
PMH40 - COST-MINIMISATION ANALYSIS OF SECOND GENERATION LONG ACTING INJECTABLES (RISPERIDONE , PALIPERIDONE, AND ARIPIPRAZOLE) FOR SCHIZOPHRENIA IN SPANISH MEDIUM-LONG TERM CARE PSYCHIATRIC UNITS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34977-5&doi=10.1016/j.jval.2018.09.1675
First page :
Section Title :
Open access? :
No
Section Order :
1046